BioCardia, Inc. (BCDA)
NASDAQ: BCDA · Real-Time Price · USD
1.090
-0.020 (-1.80%)
At close: May 7, 2026, 4:00 PM EDT
1.110
+0.020 (1.83%)
After-hours: May 7, 2026, 7:18 PM EDT
BioCardia Employees
As of December 31, 2025, BioCardia had 21 total employees, including 17 full-time and 4 part-time employees. The number of employees increased by 1 or 5.00% compared to the previous year.
Employees
21
Change (1Y)
1
Growth (1Y)
5.00%
Revenue / Employee
n/a
Profits / Employee
-$391,810
Market Cap
11.93M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 21 | 1 | 5.00% | 17 | 4 |
| Dec 31, 2024 | 20 | 0 | - | 17 | 3 |
| Dec 31, 2023 | 20 | -16 | -44.44% | 16 | 4 |
| Dec 31, 2022 | 36 | 1 | 2.86% | 30 | 6 |
| Dec 31, 2021 | 35 | 6 | 20.69% | 28 | 7 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Lunai Bioworks | 29 |
| Passage Bio | 24 |
| Moleculin Biotech | 17 |
| Reviva Pharmaceuticals Holdings | 14 |
| BioVie | 13 |
| Quoin Pharmaceuticals | 6 |
| Jupiter Neurosciences | 5 |
| Kairos Pharma | 4 |
BCDA News
- 17 days ago - BioCardia and Japan PMDA Align on Acceptability of CardiAMP Clinical Data to Support Regulatory Approval in Ischemic Heart Failure - GlobeNewsWire
- 6 weeks ago - BioCardia Earnings Call Transcript: Q4 2025 - Transcripts
- 6 weeks ago - BioCardia Reports 2025 Business Highlights and Financial Results - GlobeNewsWire
- 7 weeks ago - BioCardia to Host 2025 Financial Results and Corporate Update Conference Call on March 24, 2026 - GlobeNewsWire
- 3 months ago - BioCardia Files Pre-Submission for FDA Approval of Helix™ Transendocardial Delivery Catheter for Therapeutic and Diagnostic Agent Delivery to the Heart - GlobeNewsWire
- 5 months ago - BioCardia Cell Therapy for Ischemic Heart Failure to Progress to Formal Clinical Consultation with Japan PMDA - GlobeNewsWire
- 5 months ago - BioCardia to Present at December 2025 CSI Focus Devices in Heart Failure Congress - GlobeNewsWire
- 5 months ago - BioCardia Strengthens Leadership Team with The Addition of Farhan Shahab as Vice President of Quality - GlobeNewsWire